<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02068404</url>
  </required_header>
  <id_info>
    <org_study_id>PK/PD_Nifedipine</org_study_id>
    <nct_id>NCT02068404</nct_id>
  </id_info>
  <brief_title>Nifedipine Pharmacokinetics and Pharmacodynamics When Used as a Tocolytic in Acute Threatened Preterm Labour</brief_title>
  <official_title>Nifedipine Pharmacokinetics and Pharmacodynamics When Used as a Tocolytic in Patients Hospitalized for Acute Threatened Preterm Labour</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chantal Csajka</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preterm birth is the leading cause of perinatal mortality and morbidity. According to WHO, 15
      million children are born prematurely (gestational age &lt; 37 weeks) in the world each year
      while 7% of them die because of complications associated with prematurity. Despite constant
      improvement of obstetrical care, the number of preterm births has increased over the last
      decades and prematurity is still the most frequent cause of prenatal hospitalization in
      industrialized countries.

      The American College of Obstetricians and Gynecologists as well as the Royal College of
      Obstetricians and Gynaecologists recommend nifedipine as a first-line tocolytic in case of
      acute threatened preterm labour. Clinical experience show however an important variability in
      treatment response among pregnant women. In spite of its large use in obstetrics as a
      tocolytic agent, nifedipine is prescribed off-label. As a consequence no international
      consensus on optimal dose schedule has so far been proposed.

      Small sample size and heterogeneousness of tocolysis administration protocols make it
      difficult to compare the little data available on the pharmacokinetics of nifedipine in
      pregnant women. Nevertheless an important interindividual variability in concentrations has
      been identified (CV=12-76%) but very few studies have investigated the possible reasons of
      this variability in pregnant women. Genetic and environmental factors involved in drug
      distribution and metabolism (e.g. enzymatic activity, CYP 3A5 genotype) might partially
      explain variability in drug levels and therefore differences in treatment response.

      The goal of this study is to quantify the variability in nifedipine pharmacokinetics and
      identify potential genetic and non-genetic sources of variability in nifedipine
      pharmacokinetics in pregnant women. The relationship between concentration and treatment
      response will be evaluated and will serve to propose optimal dosage regimen to improve
      efficacy and reduce side effects associated with this treatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nifedipine blood concentration</measure>
    <time_frame>Blood collection during hospital stay for threatened preterm labour between 20-34 weeks of gestational age (together with routine blood sampling)</time_frame>
    <description>In total, 3 blood samples are collected after nifedipine administration during hospitalization at the same moment as routine blood sampling. Therefore collection hours are not specified.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genotyping</measure>
    <time_frame>Blood collection during hospital stay for threatened preterm labour between 20-34 weeks of gestational age (together with nifedipine blood sampling)</time_frame>
    <description>Pharmacogenetic analysis of genes involved in drug distribution, metabolism and action (e.g. CYP 3A5, POR, CACNA1C) are performed on blood cells of one nifedipine blood sample taken during hospitalization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phenotyping</measure>
    <time_frame>Blood collection during hospital stay for threatened preterm labour between 20-34 weeks of gestational age (together with routine blood sampling)</time_frame>
    <description>Phenotyping of CYP 3A activity is performed during hospitalization by midazolam administration as a probe. Blood is taken at the same moment as routine blood sampling. Therefore collection hour is not specified.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nifedipine side effects (feeling)</measure>
    <time_frame>Evaluation during hospital stay for threatened preterm labour between 20-34 weeks of gestational age (at 1-3 h after nifedipine administration)</time_frame>
    <description>Nifedipine side effects are collected by questioning patients during hospitalization approximately at 1-3 h after nifedipine administration to assess security of tocolysis (e.g. headache, erythema, nausea).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal heart rate (measurement)</measure>
    <time_frame>Evaluation during hospital stay for threatened preterm labour between 20-34 weeks of gestational age (at 1-3 h after nifedipine administration)</time_frame>
    <description>Maternal heart rate is measured by blood pressure meter during hospitalization approximately at 1-3 h after nifedipine administration to assess security of tocolysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal blood pressure (measurement)</measure>
    <time_frame>Evaluation during hospital stay for threatened preterm labour between 20-34 weeks of gestational age (at 1-3 h after nifedipine administration)</time_frame>
    <description>Maternal blood pressure is measured by blood pressure meter during hospitalization approximately at 1-3 h after nifedipine administration to assess security of tocolysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal heart rate (measurement)</measure>
    <time_frame>Evaluation during hospital stay for threatened preterm labour between 20-34 weeks of gestational age (during 30-60 min after nifedipine administration)</time_frame>
    <description>Fetal heart rate is measured by cardiotocography during hospitalization approximately during 30-60 min after nifedipine administration to assess security of tocolysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine contraction (measurement)</measure>
    <time_frame>Evaluation during hospital stay for threatened preterm labour between 20-34 weeks of gestational age (during 30-60 min after nifedipine administration)</time_frame>
    <description>Uterine contraction is measured by cardiotocography during hospitalization approximately during 30-60 min after nifedipine administration to assess efficacy of tocolysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine contraction (feeling)</measure>
    <time_frame>Evaluation during hospital stay for threatened preterm labour between 20-34 weeks of gestational age (during 2 h after nifedipine administration)</time_frame>
    <description>Frequency and intensity of uterine contraction are collected by questioning patients during hospitalization approximately during 2 h after nifedipine administration to assess efficacy of tocolysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth date</measure>
    <time_frame>Data collection after hospital stay for threatened preterm labour between 20-34 weeks of gestational age (potentially at 20-41 weeks of gestational age)</time_frame>
    <description>Time between hospitalization for acute threatened preterm labour and effective birth date is calculated to assess efficacy of tocolysis. This time can be extremely short (inefficacy of tocolysis and delivery in next few hours/days) or correspond to full term.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Preterm Labor</condition>
  <arm_group>
    <arm_group_label>Nifedipine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine</intervention_name>
    <arm_group_label>Nifedipine</arm_group_label>
    <other_name>Adalat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women under nifedipine treatment for acute threatened preterm labour

          -  Hospitalization for this condition in the maternity of the University Hospital of
             Lausanne (CHUV)

          -  Gestational age of 20-34 weeks

          -  Signed informed consent

        Exclusion Criteria:

          -  Patient &lt; 18 years

          -  Contraindication to tocolysis for clinical reasons (e.g. severe pre-eclampsia,
             chorioamnionitis, placental anomaly, letal fetal anomaly, important intrauterine
             growth restriction) or current labour

          -  Contraindication to nifedipine

          -  Severe renal or hepatic impairment

          -  Fever &gt; 37.5Â°C

          -  Incapacity of communication
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice Panchaud, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alice Panchaud, PhD</last_name>
    <phone>0213144276</phone>
    <phone_ext>+41</phone_ext>
    <email>Alice.Panchaud@chuv.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chantal Csajka, Prof PhD</last_name>
    <phone>0213144263</phone>
    <phone_ext>+41</phone_ext>
    <email>Chantal.Csajka@chuv.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Panchaud, PhD</last_name>
      <phone>0213144276</phone>
      <phone_ext>+41</phone_ext>
      <email>Alice.Panchaud@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Alice Panchaud, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Baud, MD PhD MER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chantal Csajka, Prof PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chin B Eap, Prof PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karine Lepigeon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Etienne Weisskopf, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2014</study_first_submitted>
  <study_first_submitted_qc>February 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2014</study_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Chantal Csajka</investigator_full_name>
    <investigator_title>Prof PhD</investigator_title>
  </responsible_party>
  <keyword>Tocolysis</keyword>
  <keyword>Preterm labor</keyword>
  <keyword>Nifedipine</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nifedipine</mesh_term>
    <mesh_term>Tocolytic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

